Grace Therapeutics, Inc. (GRCE): Total Liabilities
$2.76M
As of 2026-03-31
$1.86M
As of 2026-06-30
-37.3%
3-year compound annual growth
-16.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $2.76M | -48.8% | 2026-06-18, Balance as of period end |
| 2025-03-31 | $5.38M | -53.4% | 2026-06-18, Balance as of period end |
| 2024-03-31 | $11.56M | +3.5% | 2025-06-23, Balance as of period end |
| 2023-03-31 | $11.17M | -45.1% | 2024-06-21, Balance as of period end |
| 2022-03-31 | $20.35M | +199.4% | 2023-06-23, Balance as of period end |
| 2021-03-31 | $6.80M | -31.0% | 2022-06-21, Balance as of period end |
| 2020-03-31 | $9.86M | -61.9% | 2021-06-22, Balance as of period end |
| 2019-03-31 | $25.85M | n/a | 2020-06-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | $2.76M | -48.8% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $8.02M | +180.4% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $9.90M | -84.6% |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $44.59M | -16.7% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $9.91M | -72.7% |
| Rallybio Corp (RLYB) | 2025-12-31 | $4.30M | -33.3% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $5.93M | -46.4% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $28.52M | -23.6% |
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $8.89M | -13.2% |
Compare GRCE, CNTX, SPRO, HOWL side by side · Screen every company in Pharmaceutical Preparations ↗